Related Experiment Video
Updated: Sep 12, 2025
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.0K
Mepolizumab for severe eosinophilic asthma
Maria Kallieri1, Andriana I Papaioannou2, Stelios Loukides1
12nd Respiratory Medicine Department, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.
Expert Review of Respiratory Medicine
|August 9, 2025
Summary
Mepolizumab, a biologic therapy targeting Interleukin 5, offers significant benefits for severe eosinophilic asthma patients. It reduces exacerbations and improves quality of life, potentially modifying airway remodeling for disease control.
Area of Science:
- Respiratory Medicine
- Immunology
- Pharmacology
Background:
- Severe eosinophilic asthma is a distinct phenotype requiring systemic corticosteroids.
- Mepolizumab targets Interleukin 5, a key mediator in eosinophilic inflammation.
Purpose of the Study:
- To review the clinical development, efficacy, and safety of mepolizumab.
- To explore mepolizumab's role in achieving clinical remission and modifying airway remodeling.
Main Methods:
- Literature search of PubMed database up to June 2025.
- Inclusion of randomized controlled trials, observational studies, and mechanistic investigations.
Main Results:
- Mepolizumab significantly reduces asthma exacerbations and improves quality of life and lung function.
- Emerging evidence suggests mepolizumab may modify airway remodeling, indicating disease-modifying potential.
Conclusions:
- Mepolizumab represents a significant advancement in personalized medicine for severe eosinophilic asthma.
- It offers benefits beyond symptom control, acting as a potential disease-modifying therapy.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
459
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
459
01:19Antiasthma Drugs: Leukotriene Modifiers
470
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
470
01:24Antiasthma Drugs: Methylxanthines
400
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
400
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:26COPD: Management Using Bronchodilators and Corticosteroids
310
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
310
01:17Drugs Used in Lower Respiratory Disorders: Overview
583
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
583